2 3 2. Period of Exercise. Except as set forth in Section 3 below, this Warrant may be exercised at any time or from time to time (an "EXERCISE DATE") during the period (the "EXERCISE PERIOD") beginning on (a) the date hereof and ending (b) at 5:00...Entremed Inc • August 10th, 1999 • Services-medical laboratories
AGREEMENTAgreement • March 31st, 1999 • Entremed Inc • Services-medical laboratories • Delaware
1 EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of July 27, 1999, by and among ENTREMED, INC., a corporation organized under the laws of the State of Delaware (the "COMPANY"), and the undersigned...Registration Rights Agreement • August 10th, 1999 • Entremed Inc • Services-medical laboratories • New York
1 EXHIBIT 10.25License Agreement • April 10th, 1997 • Entremed Inc • Services-medical laboratories • Massachusetts
1 AMENDMENT NO. 2 TO PURCHASE AGREEMENT BETWEEN BIOVENTURE INVESTMENTS KFT AND ENTREMED, INC. THIS AMENDMENT NO. 2 TO PURCHASE AGREEMENT (the "Amendment") is made and entered into on this 30th day of July, 2001 by and between EntreMed, Inc., a...Purchase Agreement • August 14th, 2001 • Entremed Inc • Biological products, (no disgnostic substances) • New York
1,450,000 Shares ENTREMED, INC. Common Stock UNDERWRITING AGREEMENTEntremed Inc • February 27th, 2001 • Biological products, (no disgnostic substances) • New York
1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this "AGREEMENT"), dated as of July 22, 1999, by and among ENTREMED, INC., a corporation organized under the laws of the State of Delaware (the "COMPANY"), and the purchasers...Securities Purchase Agreement • August 10th, 1999 • Entremed Inc • Services-medical laboratories • New York
CASI Pharmaceuticals, Inc. 15,853,658 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • March 26th, 2021 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of up to 18,231,706 shares of its common stock, par value $0.01 per share (the “Shares”). The 15,853,658 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,378,048 Shares, which are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Oppenheimer & Co. Inc. (“OpCo”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean OpCo, as Underwriter, and th
EXECUTION VERSION PURCHASE AGREEMENTPurchase Agreement • August 14th, 2001 • Entremed Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 4.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "AGREEMENT"), dated as of December 14, 2001, is entered into by and among EntreMed, Inc., a Delaware corporation, with headquarters located at 9640 Medical Center Drive,...Securities Purchase Agreement • January 16th, 2002 • Entremed Inc • Biological products, (no disgnostic substances) • New York
WITNESSETHLicense Agreement • April 10th, 1997 • Entremed Inc • Services-medical laboratories • Massachusetts
EXHIBIT 4.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of December 14, 2001, is entered into by and among EntreMed, Inc., a Delaware corporation, with headquarters located at 9640 Medical Center...Registration Rights Agreement • January 16th, 2002 • Entremed Inc • Biological products, (no disgnostic substances) • New York
1 ENTREMED, INC. EXHIBIT 10.31 LEASE AGREEMENT THIS LEASE AGREEMENT, made this 10TH day of June, 1998 by and between RED GATE III LIMITED PARTNERSHIP ("LANDLORD") and ENTREMED, INC. ("TENANT"). W I T N E S S E T H: 1. DEMISE OF PREMISES Landlord...Lease Agreement • March 31st, 1999 • Entremed Inc • Services-medical laboratories
ENTREMED, INC. SERIES 2 STOCK PURCHASE WARRANTEntremed Inc • August 10th, 1999 • Services-medical laboratories • New York
RESEARCH AGREEMENTResearch Agreement • March 30th, 2000 • Entremed Inc • Services-medical laboratories • Massachusetts
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • July 19th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $.01 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
FORM OF SECURITIES PURCHASE AGREEMENTForm of Securities Purchase Agreement • October 19th, 2017 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 13, 2017, between CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
BACKGROUNDTransition Agreement • April 25th, 2003 • Entremed Inc • Biological products, (no disgnostic substances) • Maryland
20,000,000 Shares CASI Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2020 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 20,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 3,000,000 shares (the “Company Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Company Option Shares are collectively called the “Shares.”
FORM OF COMMON STOCK PURCHASE WARRANT entremed, inc.Entremed Inc • March 6th, 2013 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September ___, 2013 (the “Initial Exercise Date”) and on or prior to the close of business on the third anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from EntreMed, Inc., a Delaware corporation (the “Company”), up to _____ shares (subject to adjustments as provided below) (the “Warrant Shares”) of Common Stock.
1 EXHIBIT 10.30 AMENDMENT TO SPONSORED RESEARCH AGREEMENT This is the first Amendment, signed on December 6, 2000 (hereinafter the "Effective Date of the Amendment"), to the Sponsored Research Agreement dated June 24, 1999 (hereinafter "the...Sponsored Research Agreement • March 30th, 2001 • Entremed Inc • Biological products, (no disgnostic substances)
CASI PHARMACEUTICALS, inc. cOMMON STOCK SALES AGREEMENTSales Agreement • October 29th, 2021 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
STRICTLY CONFIDENTIAL CASI Pharmaceuticals, Inc.Letter Agreement • October 19th, 2017 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
STANDBY EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • June 28th, 2011 • Entremed Inc • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT dated as of June 28, 2011 (this “Agreement”) between YA GLOBAL MASTER SPV LTD., a Cayman Islands exempt limited partnership (the “Investor”), and ENTREMED, INC. a corporation organized and existing under the laws of the State of Delaware (the “Company”).
WHARTON CAPITAL MARKETS LLCEntremed Inc • April 16th, 2010 • Biological products, (no disgnostic substances) • New York
INVESTMENT AGREEMENTInvestment Agreement • September 19th, 2014 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This INVESTMENT AGREEMENT (this “Investment Agreement”) is made as of September 17, 2014 by and between CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Investor”).
LICENSE AGREEMENT This Agreement (the "AGREEMENT") is effective January 18, 2002 ("the EFFECTIVE DATE") by and between, on the one hand, ALLERGAN SALES, INC., a California corporation, located at 2525 Dupont Drive, Irvine, California 92612-1599, and...Restricted Securities Purchase Agreement • March 15th, 2002 • Entremed Inc • Biological products, (no disgnostic substances) • Delaware
employment agreementEmployment Agreement • October 24th, 2018 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Maryland
This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of September 28, 2018, by and between CASI PHARMACEUTICALS, INC., a Delaware corporation having its principal office at 9620 Medical Center Drive, Suite 300, Rockville, MD 20850 (the “Company”) and GEORGE CHI (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2009 • Entremed Inc • Biological products, (no disgnostic substances) • Maryland
This EMPLOYMENT AGREEMENT (“Agreement”), effective as of January 1, 2009, is by and between EntreMed, Inc., a Delaware corporation having its principal office at 9640 Medical Center Drive, Rockville, MD 20850 (the “Company”) and Mark R. Bray (the “Executive”).
EntreMed-Covance Agreement BIOPROCESSING SERVICES AGREEMENT This manufacturing services agreement dated this 7th day of July 1999 (the "Agreement") between EntreMed, Inc. a Delaware corporation ("Sponsor") having its principal place of business at...Bioprocessing Services Agreement • November 12th, 1999 • Entremed Inc • Services-medical laboratories • Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • June 6th, 2006 • Entremed Inc • Biological products, (no disgnostic substances) • Maryland
This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of the date of signature by and between ENTREMED, INC., a Delaware corporation having its principal office at 9640 Medical Center Drive, Rockville, MD 20850 (the “Company”) and Cynthia Wong (the “Executive”).
10,727,500 Shares ENTREMED, INC. Common Stock PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 13th, 2006 • Entremed Inc • Biological products, (no disgnostic substances) • New York
EntreMed, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell up to an aggregate of 10,727,500 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”) to certain investors (each an “Investor” and, collectively, the “Investors”). The Company desires to engage ThinkEquity Partners LLC (“ThinkEquity”) as lead placement agent, and Rodman & Renshaw, LLC (“Rodman” and together with ThinkEquity, the “Placement Agents”) as co-placement agent, as set forth herein in connection with such issuance and sale. ThinkEquity is acting as representative of the Placement Agents (the “Representative”). The Shares are more fully described in the Registration Statement (as hereinafter defined).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 23rd, 2018 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of _______, 2018, between CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 13th, 2015 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is made as of September 20, 2015, between CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), [________________], a company formed under the laws of [_________] (“[______]”) and any Person that delivers any portion of the Subscription Amount pursuant to Section 2.02(b) of this Agreement (such Persons, together with [______], jointly and severally, and including their successors and assigns, the “Purchaser”).
ContractExclusive Distribution Agreement • April 26th, 2023 • CASI Pharmaceuticals, Inc (DE) • Biological products, (no disgnostic substances)
Certain confidential information contained in this document, marked by brackets and *** asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.
